Analyte affinity capture by surface-immobilized diagnostic agents is a routinely used assay format for profiling numerous medically and technologically important target analytes. These assays suffer from numerous performance limitations, including sensitivity and rapidity. Assay miniaturization is advocated to improve surfacecapture performance, specifically exploiting the inverse relationship between analyte flux and capture feature size under mass transfer-limiting capture conditions that characterize many such assay formats. Reduced capture feature sizes, e.g., microarrays, are proposed to overcome mass transfer limitations, yet this is difficult to achieve across several size scales. This study validates certain advantages advocated for capture spot miniaturization using a rationale to understand surface capture miniaturization strategies. Experimentally derived immobilized ligand and target capture densities as a function of microspot size for DNA oligomers immobilized on model gold substrates are compared directly with theoretical analysis, validating the hypothesis that miniaturization yields many practical assay advantages. Specifically, results show that transitions from assay mass transfer limiting to kinetically limiting conditions as feature size decreases identify an optimal microspot size range for a specific bioassay system. Analytical advantages realized from such assay miniaturization are more uniform target-spot coverage and substantially increased rate of capture (hybridization), increasing assay signal and rapidity.bioassay ͉ mass transport ͉ miniaturization N ew strategies to improve bioanalytical methods, clinical assay designs, diagnostic devices, and rapid screening tools for disease biomarkers, biosecurity threats, and food pathogens have nearly universally emphasized miniaturization as a route to improve performance, cost, convenience, speed-to-answer, and portability. Reducing size scales for these applications has many practical implications to the measurement of biological analytes and such assay designs. Optimal device sizing is a key design feature for assays that commonly involve affinity binding of analytes to surfaces. Surface capture microassays employ diverse affinity reagents (e.g., antibodies, aptamers, and DNA) to capture broad varieties of analytes (e.g., small molecules, peptides, proteins, nucleic acids, and pathogens). Without active transport (e.g., stirring or field-induced), all current microassay platforms suffer from severe mass transfer limitations, that is, rates of analyte transport to the assay capture surface significantly lag rates of analyte binding. This problem is particularly important in producing rapid results in DNA microassays, where resulting DNA-DNA charge-charge interactions produce complications. A long-standing yet experimentally tentative assertion is that surface capture assays benefit significantly from reduced capture feature (i.e., microarray spot) size, specifically, that these assay systems capitalize on the inverse relationship between an...